Leading seed-to-sale cannabis software firm BioTrackTHC, a wholly owned subsidiary of Helix TCS Inc. (OTCQB: HLIX), continues its international expansion with new customers serving medical market cannabis producers in Australia and New Zealand.
The demand for medical marijuana in both Australia and New Zealand continues to rise as these strictly medicinal markets begin to lay the groundwork to establish safe and transparent patient access, making reliable and secure seed-to-sale tracking software essential to the industry’s success.
Headquartered in Fort Lauderdale, BioTrackTHC COO Dr. Moe Afaneh noted the company’s offices in Argentina, Colorado, Hawaii, Puerto Rico and Washington provide ideal positioning to service international businesses in the global cannabis market by spanning a variety of time zones and offering support during key business hours.
“BioTrackTHC can service businesses in countries halfway around the world because of our geographically distributed Â team,” Afaneh said. “With support spanning more than four time zones, we are confident in our ability to support the medical cannabis operators in Australia and New Zealand as they prepare to launch and scale their businesses.”
Because of the company’s background in pharmaceutical drug tracking, intersecting with its experience tracking cannabis in the U.S., the BioTrack team is able to provide unparalleled expertise to growing businesses in markets that treat cannabis more similarly to traditional prescription drugs. In addition to that blended experience, BioTrackTHC has a proven track record as a trusted choice for full-vertical tracking and dispensary point of sale for countries around the world and is able to support emerging international distribution.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…